The European Association of Urology (EAU) 2016 Congress was commenced on March 11, 2016. Invited by the organizing committee and on behalf of Dr. Ding-Wei Ye, MD, Principal Investigator of the Phase II trial and the Vice President of the Fudan University-affiliated Shanghai Cancer Center, Professor Bo Dai from Department of Urology, Fudan University-affiliated Shanghai Cancer Center gave a live presentation at the Congress on the “the Interim Results of China Phase II Clinical Trial of APL-1202, an Oral metaP2 Inhibitor, in Patients with High-Risk NMIBC and Relapsed after Intravesical Therapies”. The presentation was well received by the participating experts from around the world. The Congress’ organizing committee congratulated Professor Bo Dai and expressed interest in learning about the results from subsequent trials of APL-1202.
